An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Clinical trial NCT00207116 · COMPLETED

Trial details

NCT number: NCT00207116
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis

Start date: 2005-09-01
Primary completion: 2006-03-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.